Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.

Cancer investigation - 1 Oct 2010

Wozniak Agnieszka, Floris Giuseppe, Debiec-Rychter Maria, Sciot Raf, Schöffski Patrick

Abstract excerpt

The receptor tyrosine kinase inhibitors, imatinib and sunitinib, have significantly improved the prognosis for patients with advanced gastrointestinal stromal tumors (GISTs). Most GISTs exhibit mutations in the genes encoding the stem cell factor receptor (KIT) or platelet-derived growth factor r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Gastrointestinal Stromal Tumors
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sunitinib

Share to Transcriptional Activation

Source

Identifiers

PMID: 20690803
DOI: 10.3109/07357907.2010.494322

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20690803-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.PMID 20690803Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

The role of KIT in the management of patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular basis and management of gastrointestinal stromal tumors.Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.Semantic proximity Read ↗

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Semantic proximity Read ↗

New paradigms in gastrointestinal stromal tumour management.Semantic proximity Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.Semantic proximity Read ↗

Clinical implications of KIT and PDGFRA genotyping in GIST.Semantic proximity Read ↗

Gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.